Latest Genomic Health (GHDX) Headlines
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year
PRWeb - Thu Mar 06, 8:11AM CST
The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to be held in San Francisco, CA on April 16-17, 2014.
Downtrend Call Working As Genomic Health Stock Falls 13.7% (GHDX)
Comtex SmarTrend(R) - Mon Mar 03, 10:59AM CST
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 1 month, Genomic Health has returned 13.68% as of today's recent price of $26.07.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Concise Analysis of the International Cancer Test Market
M2 - Thu Feb 27, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbhbjn/cancer_test) has announced the addition of the "Concise Analysis of the International Cancer Test Market" report to their offering. Cancer is the second-leading cause of death and disability in the world, behind only heart disease. More people die from cancer every year around the world than AIDS, Tuberculosis and Malaria combined. Cancer testing has tremendous growth opportunities for the next five years. According to the National Cancer Institute (NCI), 85% of cancer patients are treated in community-based, private practice oncology settings. Accordingly, global expansion of cancer marker technologies may be fueled by an increased marketing of new diagnostic tests to physicians. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. The anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The global cancer test market is expected to be more than US$ 14 Billion by 2018. This study provides a comprehensive assessment of the fast-evolving, high-growth of Cancer Test market segment. This page report with 52 Figures and 57 Tables studies the Cancer Test Platform of 20 Companies. This report is broadly divided into 8 chapters. Key Topics Covered: Table of Contents 1. Executive Summary 2. Global - Cancer Testing Market and New Cases 3. Global - Cancer Testing Market Share 4. Global - Segment Wise Cancer Testing Market 5. Global - Organ Specific Cancer Testing Market 6. Cancer Diagnostics- Companies Novel Test Platforms & Pipeline Analysis (20 Companies Analysis) Companies Mentioned: - Abbott - BD Diagnostics - Beckman Coulter - BioCurex - Cepheid - CytoCore - DiagnoCure - Gen-Probe - Genomic Health - Myriad Genetics - Panacea Pharmaceuticals - QIAGEN Marseille (Earlier Ipsogen) - Qiagen - Radient Pharmaceuticals - Roche - Siemens Heathcare Diagnostics - TrovageneInc. - Ventana Medical Systems - Vermillion - bioMerieux For more information visit http://www.researchandmarkets.com/research/lb...ancer_test
What Makes Genomic Health (GHDX) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:45AM CST
Genomic Health sees significant price decline in the past month along with falling earnings estimates
Commit To Buy Genomic Health At $22.50, Earn 8.4% Annualized Using Options
at The Street - Tue Feb 11, 10:24AM CST
Investors considering a purchase of Genomic Health stock, but tentative about paying the going market price of $27.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
Genetic Testing Market Likely to Grow at a CAGR of Around 9% During 2012-2017
M2 - Tue Feb 11, 9:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/qnk984/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook to 2017" report to their offering. A recent report, Genetic Testing Market Outlook to 2017, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in around a 140-page report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2012-2017. The report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications. The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report. Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth. Companies Mentioned: - Abbott Laboratories - Clarient (GE Healthcare) - Dako (Agilent Technologies) - Genomic Health - Genoptix (Novartis) - Gen-Probe (Hologic) - Life Technologies Corporation - Myriad Genetics - Quest Diagnostics - Roche Diagnostics - Sequenom - Transgenomic For more information visit http://www.researchandmarkets.com/research/qn...ic_testing About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Downgrade Alert for Genomic Health (GHDX)
Comtex SmarTrend(R) - Fri Feb 07, 7:03AM CST
Genomic Health (NASDAQ:GHDX) was downgraded from Outperform to Neutral at Credit Suisse today. The stock closed yesterday at $26.66 on volume of 456,000 shares, above average daily volume of 191,000. Genomic Health share prices have moved between a 52-week high of $97.24 and a 52-week low of $19.00 and closed yesterday at 40% above that low price at $26.66 per share. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 1.9%.
Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:43AM CST
The shares of Genomic Health Inc. fell nearly 9% on the day.This continues the most recent downtrend for GHDX, as the stock is down nearly 19% since Jan 22.This medical research company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 05, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Q4 Loss Narrower Than Expected at Genomic, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:30AM CST
Genomic Health posted fourth-quarter 2013 adjusted loss per share of 1 cent
Genomic Health Announces Year-End 2013 Financial Results, Provides 2014 Financial Outlook
PR Newswire - Tue Feb 04, 3:01PM CST
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2013.
NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
PR Newswire - Thu Jan 30, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.
Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium
PR Newswire - Wed Jan 29, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype DX® colon cancer test studies that were recently presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI). Presentations highlighted the robust body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions, underscoring the practice-changing value of this test.
Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on Tuesday, February 4, 2014
PR Newswire - Tue Jan 28, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 4 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2013 financial results. The call and webcast will follow the release of the fourth quarter financial results after market close.
PwC Upholds 80-Year Tradition Overseeing Oscars® Balloting and Preserving Secrets for Hollywood's Biggest Night
PR Newswire - Thu Jan 23, 8:00AM CST
This year PwC celebrates its 80th anniversary leading the Oscars® balloting process on behalf of the Academy of Motion Picture Arts and Sciences (the Academy). The firm also announced today that Brian Cullinan, chairman of PwC's U.S. board of partners and managing partner of PwC's Southern California practice, has joined the leadership team managing the 2014 balloting process alongside Rick Rosas. They will be the only two people in the world who know the identities of the Oscar® winners before they are revealed on ABC's live telecast at 4 p.m. PT (7 p.m. ET) on Sunday, March 2, 2014.
Peoples Bancorp Inc. Announces 32% Year-over-year Increase in 4th Quarter Earnings
PR Newswire - Thu Jan 23, 6:50AM CST
Summary fourth quarter and full year 2013 results:
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year
PRWeb - Thu Mar 06, 8:11AM CST
The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to be held in San Francisco, CA on April 16-17, 2014.
Downtrend Call Working As Genomic Health Stock Falls 13.7% (GHDX)
Comtex SmarTrend(R) - Mon Mar 03, 10:59AM CST
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 1 month, Genomic Health has returned 13.68% as of today's recent price of $26.07.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Concise Analysis of the International Cancer Test Market
M2 - Thu Feb 27, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbhbjn/cancer_test) has announced the addition of the "Concise Analysis of the International Cancer Test Market" report to their offering. Cancer is the second-leading cause of death and disability in the world, behind only heart disease. More people die from cancer every year around the world than AIDS, Tuberculosis and Malaria combined. Cancer testing has tremendous growth opportunities for the next five years. According to the National Cancer Institute (NCI), 85% of cancer patients are treated in community-based, private practice oncology settings. Accordingly, global expansion of cancer marker technologies may be fueled by an increased marketing of new diagnostic tests to physicians. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. The anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The global cancer test market is expected to be more than US$ 14 Billion by 2018. This study provides a comprehensive assessment of the fast-evolving, high-growth of Cancer Test market segment. This page report with 52 Figures and 57 Tables studies the Cancer Test Platform of 20 Companies. This report is broadly divided into 8 chapters. Key Topics Covered: Table of Contents 1. Executive Summary 2. Global - Cancer Testing Market and New Cases 3. Global - Cancer Testing Market Share 4. Global - Segment Wise Cancer Testing Market 5. Global - Organ Specific Cancer Testing Market 6. Cancer Diagnostics- Companies Novel Test Platforms & Pipeline Analysis (20 Companies Analysis) Companies Mentioned: - Abbott - BD Diagnostics - Beckman Coulter - BioCurex - Cepheid - CytoCore - DiagnoCure - Gen-Probe - Genomic Health - Myriad Genetics - Panacea Pharmaceuticals - QIAGEN Marseille (Earlier Ipsogen) - Qiagen - Radient Pharmaceuticals - Roche - Siemens Heathcare Diagnostics - TrovageneInc. - Ventana Medical Systems - Vermillion - bioMerieux For more information visit http://www.researchandmarkets.com/research/lb...ancer_test
What Makes Genomic Health (GHDX) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:45AM CST
Genomic Health sees significant price decline in the past month along with falling earnings estimates
Commit To Buy Genomic Health At $22.50, Earn 8.4% Annualized Using Options
at The Street - Tue Feb 11, 10:24AM CST
Investors considering a purchase of Genomic Health stock, but tentative about paying the going market price of $27.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
Genetic Testing Market Likely to Grow at a CAGR of Around 9% During 2012-2017
M2 - Tue Feb 11, 9:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/qnk984/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook to 2017" report to their offering. A recent report, Genetic Testing Market Outlook to 2017, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in around a 140-page report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2012-2017. The report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications. The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report. Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth. Companies Mentioned: - Abbott Laboratories - Clarient (GE Healthcare) - Dako (Agilent Technologies) - Genomic Health - Genoptix (Novartis) - Gen-Probe (Hologic) - Life Technologies Corporation - Myriad Genetics - Quest Diagnostics - Roche Diagnostics - Sequenom - Transgenomic For more information visit http://www.researchandmarkets.com/research/qn...ic_testing About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Downgrade Alert for Genomic Health (GHDX)
Comtex SmarTrend(R) - Fri Feb 07, 7:03AM CST
Genomic Health (NASDAQ:GHDX) was downgraded from Outperform to Neutral at Credit Suisse today. The stock closed yesterday at $26.66 on volume of 456,000 shares, above average daily volume of 191,000. Genomic Health share prices have moved between a 52-week high of $97.24 and a 52-week low of $19.00 and closed yesterday at 40% above that low price at $26.66 per share. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 1.9%.
Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:43AM CST
The shares of Genomic Health Inc. fell nearly 9% on the day.This continues the most recent downtrend for GHDX, as the stock is down nearly 19% since Jan 22.This medical research company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 05, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Q4 Loss Narrower Than Expected at Genomic, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:30AM CST
Genomic Health posted fourth-quarter 2013 adjusted loss per share of 1 cent
Genomic Health Announces Year-End 2013 Financial Results, Provides 2014 Financial Outlook
PR Newswire - Tue Feb 04, 3:01PM CST
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2013.
NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
PR Newswire - Thu Jan 30, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.
Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium
PR Newswire - Wed Jan 29, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype DX® colon cancer test studies that were recently presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI). Presentations highlighted the robust body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions, underscoring the practice-changing value of this test.
Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on Tuesday, February 4, 2014
PR Newswire - Tue Jan 28, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 4 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2013 financial results. The call and webcast will follow the release of the fourth quarter financial results after market close.
PwC Upholds 80-Year Tradition Overseeing Oscars® Balloting and Preserving Secrets for Hollywood's Biggest Night
PR Newswire - Thu Jan 23, 8:00AM CST
This year PwC celebrates its 80th anniversary leading the Oscars® balloting process on behalf of the Academy of Motion Picture Arts and Sciences (the Academy). The firm also announced today that Brian Cullinan, chairman of PwC's U.S. board of partners and managing partner of PwC's Southern California practice, has joined the leadership team managing the 2014 balloting process alongside Rick Rosas. They will be the only two people in the world who know the identities of the Oscar® winners before they are revealed on ABC's live telecast at 4 p.m. PT (7 p.m. ET) on Sunday, March 2, 2014.
Peoples Bancorp Inc. Announces 32% Year-over-year Increase in 4th Quarter Earnings
PR Newswire - Thu Jan 23, 6:50AM CST
Summary fourth quarter and full year 2013 results:
